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I ABSTRACT 
 
Purpose:  
Bisphosphonate related osteonecrosis of the jaw (BRONJ) is a seide effect of long-term 
bisphosphonate therapy in cancer patients. The following document presents a cases 
review at the oral and maxillofacial department from the University Hospital in Zürich, 
Switzerland. 
 
Materials and Methods: 
This review evaluated 56 medical records of patients with Osteonecrosis of the Jaw and 
Bisphosphonate history. One record had to be excluded due to the fact that the patient 
had radiation therapy in the area of clinical symptoms. The patients who fulfilled the 
entry criteria underwent retrospective analysis. Available data on demographics, medical 
history, type and duration of BP use, possible triggering event, clinical manifestations, 
mode of therapy and outcome were recorded on different tables on an Excel programm. 
 
Results: 
BRONJ was associated with intravenosu bisphosphonates in 90.7% of the cases and 
with oral bisphosphonates in 9.2%. Of the patients, 66.6% received zolendronic IV while 
80% were taking fosamax orally. The mean duration from the first use of the drug to the 
recognition of sign or symptoms of ONJ was 39 months.The first and most frequent first 
symptom was pain. The clinical manifestation included halitosis, hypesthesia, pus 
exsudates, swelling, non-healing wounds and exposed bone. Before the occurrence of 
BRONJ, 71.7% of the patients have had one or more tooth extracted. Surgical 
treatments were done in 57.4% and no surgical treatments which involved only 
antibiotics were done in 42.5%. Of the patient 38.2% had a complete remission after 
therapy. 
 
Conclusion: 
Solutions for a better outcome after therapy for BRONJ remain elusive.  
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II INTRODUCTION 
 
Osteonecrosis, also referred to avascular necrosis of bone, aseptic necrosis, ischemic 
necrosis, or oteochondritis dissecans, is the death of a segment of bone caused by an 
imparied blood supply. This disorder can be caused by an injury or can occur 
spontaneously, but is not a specific disease but rather a condition in which there is death 
of a localized area of bone.1  
 
There are two principal groups of patients that are affected with this disorder. The first 
group suffers from osteoradionecrosis2,3,4. Its most severe form, called infected 
osteoradionecrosis (IORN), frequently presents as a chronic disease that is highly 
resistant against therapeutic interventions. The clinical symptoms include pain, chronic 
fistulation, exposed bone, and even extended bone destruction and pathological bone 
fracture3,5,6. 
 
Recently, a second type of osteonecrosis has been observed to involve the jaws during 
long term of antiresorptive bone treatment. This type was first report by Marx in 20037. 
Since then, Roelofs et al describes that there have been several clinical reports have 
emerged which report the incidence of osteonecrosis of the jaws in non radiated patients 
but who are receiving bisphosphonate therapy8.  
 
According to the American Association of Oral and Maxillofacial Surgeons (aaoms), 
bisphosphonate-related osteonecrosis of the jaw (BRONJ) is defined by three main 
characteristics: previous or current bisphosphonate therapy, exposed necrotic bone in 
the maxillofacial region that has been persisted for more than 8 weeks, and no radiation 
of the jaws9.  
If these three conditions are present, the diagnosis can be confirmed clinically. It is 
important to exclude local malignancy, trauma, periodontal disease, and lingual 
mandibular sequestration and ulceration10. 
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Bamias et all explained on his article that the incidence among cancer patients receiving 
high-dose intravenous bisphophonates shows osteonecrosis of the jaw as dependent on 
dose and duration of therapy, and has an estimated incidence of 1% to 12%9,11.   
 
Among patients treated for 4±12 months, the incidence increases with the time of 
exposure, from 1.5% to 7.7% compare to those in treatment for 37±48 months11.  
 
In a clinical report done in Thailand, BRONJ typical clinical presentation includes: pain, 
soft-tissue swelling and infection, loosening of teeth, drainage and exposed bone12. 
These described symptoms may occur spontaneously, or more commonly, at the site of 
previous tooth extraction or other local invasive procedures. Patients may also present 
with feeling of dysesthesias, heaviness and numbness of the jaw. However, BRONJ 
may remain asymptomatic not only for weeks but also months, and will only become 
evident after finding exposed bone in the jaw12.  
 
Bisphoshonates represent a family of compounds of the general structure H2PO3-
CR1R2-H2PO3. Woo & Gellstein descreibes the primary mechanism of action of 
bisphosphonates as the inhibition of osteoclastic resorption of the bone8,13. They can be 
grouped into several pharmacologic classes. The most potent class consists of nitrogen-
containing bisphosphonates such as alendronate, pamidronate, and zoledronate14.   
 
The reduction of skeletal-related events such as fractures is one of the positive effects of 
the bisphosphonates. They also prevent hypercalcaecemic episodes, reduce pain and 
LQFUHDVSDWLHQWV¶TXDOLWLW\RIOLIH15. 
 
Bisphosphonates are used in the treatment of metabolic bone diseases such as 
RVWHRSRURVLVDQG3DJHW¶VGLVHDVHRIERQHDQGDOVRDWPXFKKLJKHUGRVHVDQGSRWHQF\
in cases where cancers are involve skeletal sites, most commonly when treating multiple 
myeloma. In each of these cases the purpose of bisphosphonate treatment is to prevent 
bone loss, reduce fracture risk, and a direct anticancer effect.  
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On the other hand, adverse effects when using bisphosphonate have been observed. 
Such as: acute-phase reactions, adverse side-effects affecting the upper aerodigestive 
tract and some others affecting the kidneys15. 
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III OSTEONECROSIS OF THE JAWS 
 
III.1 Chemical Osteonecrosis 
 
Necrosis of the jaws can occur as a result of contact with caustic chemicals and 
protoplasmic poisons. The condition may arise in industrial workers exposed to noxious 
substances. Alternatively, the chemicals may be administered either therapeutically or 
inadvertently, or as a result of a clinical accident. The extent of the bone damage varies 
according to the quantity and nature of the chemical responsible, and the condition often 
is complicated further by a superimposed pyogenic infection16. 
 
 
III.1.1 Phosphorus necrosis 
 
         The most documented of the chemicals agents causing necrosis of the jaws 
is phosphorus. There is no consensus as to the exact etiology of the condition, 
but the fumes that emanate are phosphorous anhydride (P2O3) and phosphoric 
anhydride (P2O5). These, in conjunction with superadded bacterial infection, are 
considered to be responsible17. 
 
 The lesion may occur following tooth extraction or alveolar abscess even 
many months after exposure to the fumes. Kennon and Hallam17 state thath 
phosphorus necrosis may occur up to two years after a worker has left 
employment in which phosphorus fumes were present. 
 
The jaw is particulary susceptible to necrosis due to the fact that it is 
subject to pyogenic infection arising from the teeth or tooth socket and the bone 
may be infected through an abrasion in the mucosa or by ulceration of the 
gingival. 
Patients with phosphorus necrosis look and feel ill, but the temperature is 
only slightly elevated16.  
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III.2 Necrosis following therapy with 
 
III.2.1 Mercury  
 
         The disease is limited to the alveolar portion of the upper and lower jaw. 
The sequestra extruded consist of portions of alveolus with attached teeth. Bone 
changes are secondary to a mercurial stomatitis, the extension occurring from the 
necrotic gingival mucosa along the periodontal membrane of the standing teeth. 
 
III.2.2 Arsenic Trioxide  
 
Arsenic Trioxide was used to be employed to effect desvitalization of the 
dental pulp, but leakage via the tooth apex is likely to produce a localised 
necrosis of bone16. 
 
III.2.3 Radiation  
 
Radiation of bone results in permanent damage to the osteocytes and 
microvasculature system. The altered bone becomes hypoxic, hypovascular, and 
hypocellular. It is the result of nonhealing, dead bone; infection is not necessarily 
present18. 
 
Although most instances arise secondary to local trauma, a minority 
appears spontaneous. The mandible is involved most frequently, although a few 
cases have involved the maxilla. Affected areas of bone reveal ill-defined areas of 
radiolucency that may develop zones of relative radiopacy as the dead bone 
separates from the residual vital areas. Intractable pain, cortical perforation, 
fistula formation, surface ulceraton, and pathologic fracture may be present18. 
 
The radiation dose is the main factor associated with bone necrosis, 
although the volume of bone irradiated and the proximity of the maximal dosing 
both exert an effect. The risk of bone necrosis increases in the presence of the 
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following: teeth, bone trauma, periodontal disease and concurrent 
chemotherapy18. 
 
III.2.4 Bisphosphonate 
 
Bisphonate induced osteonecrosis of the jaw is refered to a condition 
characterized by exposure of bone in the mandible or maxilla persisting for more 
than 8 weeks in a patient who has taken or currently is taking a bisphosphonates 
and who has no history of radiation therapy to the jaws. However, while the 
exposed bone is indeed dead (osteonecrosis), bone death is actually a secondary 
result of bisphosphonates bone toxicity, or osteopetrosis19.  
 
Clinically, the disease presents as exposed alveolar bone, with or without 
pain, swelling and fistula formation and that occurs spontaneously or becomes 
evident following an invasive surgical procedure such as tooth removal, 
periodontal surgery, apicoectomy, or dental implant placement19,20.  
 
The disease manifests only in the jaws and to date has not been reported 
in other skeletal sites. It originates in the alveolar bone and may then extend to 
the basilar bone or ramus. Occasionally, early subclinical radiographic signs ± 
including sclerosis of the lamina dura, loss of the lamina dura and/or widening of 
the periodontal ligament space particularly in association with molar teeth19. 
 
Greenberg M, Glick M, Ship J explained that the cumulative incidence is 
rising to be 10% after 3 years of drug use of intravenous bisphosphonates; with 
oral bisphosphonates, the risk is less, but still can produce BRONJ20. 
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V. BISPHOSPHONATES  
 
 
IV.1 Bisphosphonates concept 
 
Bisphosphonates are pyrophosphate analogues, characterized by a P-C-P containing 
central structure rather than the P-O-P of pyrophosphate, and a variable side chain8. 
Coleman explained that the P-C-P backbone renders bisphosphonates resistant to the 
activity of phosphatase in order to promote their binding to the mineralised bone matrix21.  
 
An affinity for sites of active bone turnover is evident by their increased uptake in growth 
plates, bone grafts, and scans of normal maxillae and mandibles. Pyrophosphates are 
easily broken down via hydrolysis and eliminated. Because of their substion of carbon 
for oxygen in the backbone of the molecule, bisphosphonates are completely 
resistentant to hydrolytic breakdown, hence their accumulation in the bonematrix and 
extremely long half-life. In addition, substitution of nitrogen-containing side chains in the 
backbone carbon of bisphophonates increases potency21.  
 
To date, only nitrogen-containing bisphosphonates have been known to produce 
osteonecorsis of the jaws. They can be administerd either orally or intravenously21. 
 
IV.2 Modes of action 
 
The fundamental biologic action of all bisphosphonates is to inhibit bone resorption and 
hence bone turnover and renewal, which of course reuses serum calcium levels as well.  
 
The reason for this antiosteoclastic or anti-resorption effect is the inhibition and/or 
irreversible cell death of the osteoclast. Upon intravenous or oral administration, the 
bisphosphonate is bound to the mineral crystals on every bone surface. Repeated doses 
of bisphosphonate accumulate in the bone matrix.  
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During normal bone remodeling, osteoclast resorb the bone and ingest the 
bisphosphonate, which functions as an analogue of the isoprenoid diphosphate lipids 
are essential for farnesylation and geranylgeranylation of guanosine triphosphate 
(GTPase) enzymes, which prevent osteoclast apoptosis22. This biosynthetic pathway is 
also known as the mevalonate branch pathway.  
 
Microscopically, the osteoclast is observed to lose its normal ruffled border at the 
Howship lacuna resorption site; retract from the bone surface, and die. Without bone 
resorption and the concomitant release of bone induction proteins such as bone 
morphogenetic protein (BMP) and isulinlike growth factors 1 and 2 (ILG1 and ILG2), old 
bone is not removed and new osteoid is not formed.  
 
The old bone therefore survives far beyond its programmed lifespan. Since the 
osteocyte is not an inmortal cell, it eventually dies, leaving dead bone behind. The 
function of the osteocyte is to act as a mechanoreceptor to maintain the mineral matrix 
of existing bone. Therefore, if the osteocyte outlives the dictates of normal bone 
remodeling, it adds further mineral matrix to the bone. The mention  hypermineralizaton 
is observed as being associated with bisphosphonate toxicity shown as sclerosis of the 
lamina dura, which is followed by a more generalized osteosclerosis in the alveolar bone.  
 
IV.3 Pharmacocinetics 
 
Oral bisphosphonates are absorbed in the small intestines, although poorly, only 1% to 
10% is made available to bone. If the bisphosphonate is taken with meals, absorption is 
further reduced. The circulating half-life of oral and intravenous bisphosphonates ranges 
from a scant of 0.5 hours to a maximum of 2 hours. Attesting to its rapid uptake into 
bone matrix, where 30% to 70% of the intravenous or absorbed dose accumulates in 
bone. The remainder is excreted unchanged in the urine19. 
 
Repeated doses accumulate in bone matrix and can be removed only by osteoclast-
mediated resorption as part of the bone turnover cycle. Bisphonates are toxic to 
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osteoclasts and prevent bone turnover, therefore, bisphophonate bone toxicity is both 
dose and time dependent19.  
 
,Q &ROHPDQ¶V UHSRUW LW LV VWDWHG WKDW DSUR[LPDWHO\  ± 75% of the injected dose 
(Intravenous bisphosphonates) binds avidly to mineral exposed bone, where it is 
internalised by the osteoclast during bone esorption and the remainder is excreted by 
the kidney21. 
 
IV.4 Clasifications according to the WHO Colaborating Centre for Drug Statistic 
Methodology 
 
M        MUSCULO-SKELETAL SYSTEM 
M05    DRUGS FOR TREATMENT OF BONE DISEASES 
M05B   DRUGS AFFECTING BONE STRUCTURE AND       
MINERALIZATION 
M05BA Bisphosphonates 
 
 
ATC Code   Name   DDD   U  Adm.R 
M05BA01   etidronic acid  0.4  g  O  
  1.5  g  P  
M05BA02   clodronic acid  1.6  g  O  
  1.5  g  P  
M05BA03   pamidronic acid  60  mg  P  
M05BA04   alendronic acid  10  mg  O  
M05BA05   tiludronic acid  0.4  g  O  
M05BA06   ibandronic acid  6  mg  P  
  5  mg  O  
M05BA07   risedronic acid  5  mg  O  
M05BA08   zoledronic acid  4  mg  P  
 
IV.5 Bisphosphonates used in Switzerland23 
 
ACLASTA 
 ATC-Code: M05BA08 
 Swissmedic: 57363  
 Active Ingredient: Acidum Zoledronicum 
 Company: Novartis Pharma Schweiz AG, Bern 
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BONEFOS 
 ATC-Code: M05BA02 
 Swissmedic 50957, 50958 
 Active Ingredient: Dinatrii clodronas anhydricus  
 Company Bayer (Schweiz) AG, 8045 Zürich. 
 
PAMIDRONAT TEVA 
 ATC-Code: M05BA03 
 Swissmedic: 58855 
 Active Ingredient: Dinatrii pamidronas anhydricus 
 Company: Teva Pharma AG, 4147 Aesch 
 
AREDIA 
 ATC-Code: M05BA02 
 Swissmedic: 52092 
 Active Ingredient: Dinatrii pamidronas. 
 Company: Novartis Pharma Schweiz AG, Bern 
 
BONIVIA 
 ATC-Code: M05BA06  
 Swissmedic: 57526 
 Active Ingredient: Acidum ibandronicum 
 Company: Roche Pharma (Schweiz) AG, 4153 Reinach 
 
ZOMETA 
 ATC-Code: M05BA08 
 Swissmedic: 56257 
 Active Ingredient: Acidum Zoledronicum 
 Company: Novartis Pharma Schweiz AG, Bern 
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BONDRONAT 
 ATC-Code: M05BA06 
 Swissmedic: 53626, 56360, 57424 
 Active Ingredient: Acidum ibandronicum 
 Company: Roche Pharma (Schweiz) AG, 4153 Reinach 
 
There are many other bisphosphonates used in Switzerland which can be found at the 
Swiss Farmacological Compendium, those being described here had  relevanz higher as 
3%.23 
 
IV.6 Bisphosphonates used in the United States of America (According to the US Food 
and Drugs Administration FDA) 
 
DIDRONEL  
 FDA Application No.: (NDA) 017831 
 Active Ingredient:  ETIDRONATE DISODIUM 
 Company: PROCTER AND GAMBLE 
 Original Approval Date: September 1, 1977 
 
SKELID  
 FDA Application No.:  (NDA) 020707 
 Active Ingredient:  TILUDRONATE DISODIUM 
 Company: SANOFI AVENTIS US 
 Original Approval Date: March 7, 1997 
 
FOSAMAX  
 FDA Application No.: (NDA) 020560 
 Active Ingredient:  ALENDRONATE SODIUM 
 Company: MERCK AND CO INC 
 Original Approval Date: September 29, 1995 
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AREDIA  
 FDA Application No.: (NDA) 020036 
 Active Ingredient:  PAMIDRONATE DISODIUM 
 Company: NOVARTIS 
 Original Approval Date: October 31, 1991 
 
ACTONEL  
 FDA Application No.:  (NDA) 020835 
 Active Ingredient:  RISEDRONATE SODIUM 
 Company: PROCTER AND GAMBLE 
 Original Approval Date: March 27, 1998 
 
BONIVA  
 FDA Application No.:  (NDA) 021455 
 Active Ingredient:  IBANDRONATE SODIUM 
 Company: ROCHE 
 Original Approval Date: May 16, 2003 
 
ZOMETA 
 FDA Application No.:  (NDA) 021223 
 Active Ingredient:  ZOLEDRONIC ACID 
 Company: NOVARTIS 
 Original Approval Date: August 20, 2001 
 
RECLAST  
 FDA Application No.: (NDA) 022080 
 Active Ingredient:  ZOLEDRONIC ACID 
 Company: NOVARTIS PHARMS 
 Original Approval Date: August 17, 2007 
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IV.7 Medical Use: 
 
Commonly used to treat patients with osteoporosis and neoplasias, especially in the 
case of lytic bone metastases (generated from breast and prostate cancer) and multiple 
myeloma, bisphosphonates reduce such skeletal complication as pain, pathologic 
fractures, limited mobility, malignant hypercalcemia, and spinal cord compression24. 
 
Franca Dore et all explaines that intravenous bisphosphonates are primarily used as an 
effective treatment and management of cancer-related conditions. These conditions 
include hypercalcemia of malignancy, skeletal-related events associated with bone 
metastases which present solid tumors including breast cancer, prostate cancer and 
lung cancer, and last but not least in the management of lytic lesions in the setting of 
multiple myeloma. The IV bisphosphonates are effective in preventing and reducing 
hypercalcemia, stabilizing bony pathology and preventing fractures in the context of 
skeletal involvement. While they have not been shown to improve cancer-specific 
survival, they have had a significant impact on the quality of life for patients with 
advanced cancer that involves the skeletal system24. 
 
Oral bisphosphonates are approved as a treatment for osteoporosis and are frequently 
used as a treatment for osteopenia as well. They are also used for a variety of less 
FRPPRQFRQGLWLRQVVXFKDV3DJHW¶VGLVHDVHRIERQHDQGRVWHRJHQHVLV LPSHUIHFWDRI
childhood. In different clinical reports25,26 the most prevalent and common indication 
reported is , however, osteoporosis. Osteoporosis may appear in the context of other 
diseases including  inflammatory bowel disease or primary biliary cirrhosis, which are 
the result of medications, such as steroids (most commonly), or as a consequence of 
postmenopausal aging. Whatever the underlying etiology of the osteoporosis, 
bisphosphonates may play a role, perhaps in conjunction with calcium and vitamin D, in 
its management27. 
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IV.8 Treatment Benefits 
 
IV.8.1 Prevent skeletal morbidity and relief of bone pain 
 
Bisphonates provide an additional treatment approach to radiotherapy, especially 
for patients with poorly localised bone pain or recurrence of bone pain in previosly 
irradiated sites. 
Bisphonates have become the standard of care for the treatment and prevention 
of skeletal complications associated with bone metastase in patients wiht breast 
cancer and multiple myeloma21.  
 
 
IV.9 Treatment Complications 
 
:KHQ FDQFHU WKHUDSLHV DUH FRPSDUHG ELVSKRVSKRQDWH WKHUDS\ µV IUHTXHQF\ DQG
severity of adverse events are generally mild and infrequent, thus, the benefits of 
treatment with any bisphosphonate, either taken orally or intravenously, almost always 
outweight the risks. According to Coleman, the side effect profile is mostly influenced by 
the administration route. Around 15-30% of patients with intravenous bisphosphonates 
will experience an acute phase reaction characterized by transient fever with muscle and 
joint aches; however, this usually only follows the first infusion and is largely irrelevant 
thereafter. Some data suggest that the incidence of the acute phase response is lesss 
common in immunocompromised advanced cancer patients than in healthy subjects or 
in those without metastases21. 
 
IV.9.1 Renal complications:  
 
When patients are given high doses (above standard) or a rapid infusion 
with intravenous agents, renal abnormalities have been described. However, 
renal toxicity is unusual, usually predictable and reversible, when any 
bisphosphonate is given at the recommended dose and schedule. Serious 
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bisphosphonate-induced renal complications including renal failure are rare (less 
than 0.5%). 
 
Because renal dysfunction is infrequent, none of the placebo-controlled 
trials with ibandronate or zolendronic acid showed any statistically significant 
differences between active therapy and placebo in creatinine levels with time. 
However, idiosyncratic renal abnormalities undoubtely do occur. A focal 
glomerulosclerosis asssociated with nephrotic syndrome is described when using 
pamidronate whereas when using zoledronic acid,  renal abnormalities relate to 
tubular damage21. 
 
 
IV.9.2 Osteonecrosis of the jaw 
 
In recent years, BRONJ has become one of the most discussed adverse 
events in advanced malignancy. Since the original reports of ONJ associated with 
the use of bisphosphonates were produced in 2003, over 1000 other cases have 
come to the attention of regulatory authorities around the world. The 
pathogenesis of BRONJ remaisn obscure and prospective research is requierd to 
determine it21 
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V. BISPHOSPHONATES RELATED OSTEONECROSIS OF THE JAWS 
 
The AAOMS, in order to distinguish Bisphosphonates-related osteonecrosis of the jaws 
(BRONJ) from other delayed healing conditions, has adopted the following working 
definition of BRONJ: 
 
When the following characteristics are present together, a patient may be considered to 
have BRONJ: 
 
1. Current or previous treatment with a bisphosphonate; 
 
2. Exposed, necrotic bone in the maxillofacial region that has persisted for more 
than eigh weeks 
 
3. No history of radiation therapy to the jaws27. 
 
 
V.1 Risk factors 
 
The following groups including: drug-related, local risk factors and 
demographic/systemic factors have been define in order to organise the possible risk 
factors for the development of BRONJ27. 
 
V.1.1 Drug-related risk factors  
 
V.1.1.1 Particular bisphosphonate potency 
 
Zoledronate is more potent than pamidronate, which is more potent than 
the oral bisphosphonates; therefore the IV route of administration results in 
a greater drug exposure than the oral route.  
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V.1.1.2 Duration of therapy 
 
The longer duration appears to be associated with increased risk.  
 
V.1.2 Local risk factors  
 
V.1.2.1 Dentoalveolar surgery 
 
Including, but not limited to: 
1. Extractions 
2. Dental implant placement 
3. Periapical surgery 
4. Periodontal surgery (involving bone injury) 
 
Patients who while taking intravenous bisphosphonates are undergoing 
dentoalveolar surgery are at least seven times more likely to develop 
BRONJ than patients who are not having dentoalveolar surgical 
procedures.  
 
V.1.2.2  Local anatomy 
 
1. Mandible 
a. Lingual tori 
b. Mylohyoid ridge 
 
2.Maxilla 
a. Palatal tori 
 
It has been observed a 2:1 mandible-maxilla ratio representing that lesions 
are found more commonly in the mandible than the maxilla, specially in 
areas with thin mucosa overlying bony prominences such as tori, bony 
exostoses and the mylohyoid ridge.  
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V.1.2.3Concomitant oral disease 
 
The risk for developing BRONJ are seven times more in patients with a 
history of inflammatory dental disease, such as periodontal and/or dental 
abscesses 27.  
 
 
V.1.3 Demographic and systemic factors 
 
x Age 
According to the AAOMS  with each decade that passes, there is a 9% 
increased risk for BRONJ in multiple myeloma patients treated with IV 
bisphosphonates.  
 
x Race 
Caucasian 
  
x Cancer diagnosis 
Patients with multiple myeloma have a greater risk than patients with 
breast cancer; and those last ones with breast cancer have a greater risk 
than those with other cancers.  
 
x Other diagnosis 
Osteopenia/osteoporosis diagnosis concurrent with cancer diagnosis 
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V.1.4 Other risk factors 
  
The following are thought to be risk factors of BRONJ according to the AAOMS, 
 
1. Corticosteroid therapy 
2. Diabetes 
3. Smoking 
4. Alcohol use 
5. Poor oral hygiene 
6. Chemotherapeutic drugs27 
 
V.2 Manifestations 
 
The clinical description and history alone will distinguish BRONJ from the following 
conditions of delayed bone and wound healing. 
 
V.2.1 Clinical Manifestations 
 
Clinical Symptoms and lesions are rather similar to the lesions seen in patients 
with osteoradionecrosis. Necrotic bone is exposed in the oral cavity. The lesions 
are often painless; however, the patients may suffer from pain because of 
surrounding inflammatory soft tissue reactions and show symptoms and 
radiological signs of bone sequestration and /or osteomyelitis. Tooth extraction is 
very common in the history of these patients. Interestingly, this disorder seems to 
be less prominently localized in the mandible in comparison with 
osteoradionecrosis28. 
 
V.2.2 Radiographic manifestations 
 
The condition manifests at first panoramic view, with osteolysis or sequestrum in 
few patients, however with computerized tomography osteosclerosis and/or 
osteolysis is always found.29 
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Other findings include sclerosis, cortical irregularity, lucency, mottling, 
fragmentation/sequestra formation, sinus communication, and persistent sockets. 
There correlation between the anatomic location of clinical and radiographic 
findings is a high. Treister, Friedland and Woos reported in their study that in 
nearly all cases, CBCT demonstrated a greater extent and quality of changes 
compared with panoramic radiography.30 
 
 
V.2.3 Microscopic manifestatitons: 
 
Microscopically, it presents an appearance of nonspecific necrotic bone with 
some bacterial colonization, similar to that of osteomyelitis or osteoradionecrosis. 
 
Histopathologic examination revealed a necrotic osteitis associated with a 
mixed infiltrate of lymphocytes and granulocytes with medullary fibrosis and 
colonization with pathogens29. 
 
It has been found that Actinomyes is detectable in a high percentage of patients 
suffering from infected osteoradionecrosis. Interestingly, Lugassy31 et al. describe 
two patients with severe osteomyelitis and presence of Actinomyces colonies 
after bisphosphonate therapy28. 
 
 
V.3 Process 
 
The onset of osteonecrosis is related to the potency and half-life of the specific 
bisphosphonate used. The most potent, Zometa, when administered at the 
recommended dose of 4mg per month, may produce exposed bone within 6 to 12 
months32. 
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An equally potent dose of Pamidronate (ie, 90mg per month), administrated on a regular 
basis, seems to produce exposed bone in 10 to 16 months24. 
 
On the other hand oral bisphosphonate Fosamax (alendronate), when administered as 
recommended at 10mg daily or 70mg weekly, takes 3 years or more to produce bone 
exposure because of its significantly slightly shorter half-life24. 
 
All patients who received a bisphosphonate absorb a certain amount of bone toxicity. 
The jaws then undergo bone turnover/renewal at a rate 10 times faster than any other 
bone in the adult skeleton and are exposed to a tenfold greater effect from these drugs 
as a result32.  
 
V.4 American Association of Oral and Maxillofacial Surgeon presented the following 
bisphosphonate related osteonecrosis of the jaws staging  
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1ecrotic and exposed bone in the maxillofacial region without resolution in 8 to 12 
weeks in patients treated with any bisphosphonate and who have not received radiation 
therapy to the jaws. 
Á5HJDUGOHVVRIWKHGLVHDVHVWDJHthe following should be done: 
Mobile segments of bony sequestrum to be removed without exposing uninvolved bone.  
Consider to extract a symptomatic teeth within exposed, necrotic bone since it is unlikely 
that the extraction will exacerbate the established necrotic process. 
ÁNo short-term benefit, if the IV bisphosphonates is discontinued. However, if systemic 
conditions allow discontinuing for a long-term, it may be beneficial in stabilizing the sites 
of BRONJ, and it will reduce the risk of new site development, and will reduce clinical 
symptoms. The treating oncologist in consultation with the OMS and the patient should 
discuss the risks and benefits of continuing bisphosphonate therapy.  
ÁGradual improvement in clinical disease has been associated to discontinuation of oral 
bisphosphonate therapy in patients with BRONJ. 
If systemic conditions permit, modification or cessation of oral bisphosphonate therapy 
should be done in consultation with the treating physician and the patient27. 
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VI. MATERIAL AND METHODS 
 
VI.1 Patients: 
 
For Data collection, we required the electronic medical record system used by Zurich 
University Hospital (KISIM) and by the Department of Oral and Maxillofacial Surgery at 
the University Dental Clinic (VITODENT). Patients who were treated at the Department 
for Craniomaxillofacial Surgery, University Hospital of Zurich with BRONJ during 2003 
and 2009 were determined. 
 
Our inclusion criteria were that patients have clinical features of Osteonecrosis of the 
Jaw and who have a bisphosphonate history of at least 3 months, but have no history of 
radiation in head and neck area. 
 
In total we treated 56 patients with Osteonecrosis of the Jaw and Bisphosphonate 
history. Of those 56 patients, one had to be excluded due to the fact of radiation therapy 
in the area of clinical symptoms. 
 
43 (78.18%) of the patients, received chemotherapy, 6 (10.92%) had a history of stem 
cell transplantation, 10 (18.18%) underwent hormone therapy, 17 (30.91%) received 
cortisone and 1 (1.82%) received radiotherapy in the oral and neck area.  

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Figure 1: Underlying Cancer Therapy. 
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VI.2 Methods: 
 
The patients who fulfilled the entry criteria underwent retrospective analysis. Available 
data on demographics, medical history, type and duration of BP use, possible triggering 
event, clinical manifestations, mode of therapy and outcome were recorded on different 
tables on an Excel programm. 
 
The exactly groups were as follow: 
 
1. Patients data: age and sex were recollected  
2. Medical History: the underlying these of the patients was taken in consideration. 
Breast Ca., Multiple Myeloma, Prostate Ca or Osteonecrosis were expected, but 
any other disease found, was recorded as well. 
3. Bisphosphonate History: type of bisphophonate, route of administration (IV or 
oral), and the duration of the therapy in months was recorded. 
4. Clinical Manifestations: Location and distribution of the lesion, first symptomes, 
and other symptomes during the check ups were recorded 
5. Triggering events: last procedure made before finding the first lesion was 
recorded. 
6. Diagnostic Tools: they were made at the first consultation at the Clinic of the 
University hospital, not on the other clinics. And was only recorded once in this 
study. 
7. Treatment Protocols: antibiocal treatment vs surgical procedures that included 
minimal invasive curetage as well as ostectomy or extensive resection were 
recorded. 
8. Follow-up and treatment outcome: it was only recorded the information that was 
found at the moment of the data recollection, which gave us a period of 4 months 
until 4 years follow up. 
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VII. RESULTS 
 
VII.1 Patients 
 
The study group included 55 patients, with an average age of 67. Of these patients, 34 
were women (mean age, 69 years; range, 47-83 years) and 21 were men (mean age, 63 
years; range, 39-82) diagnosed as having Bisphosphonate asociated osteonecrosis of 
the Jaws.  
 
VII.2 Medical History: 
 
Of all patients, 20 (36.36%) had Breast Cancer, 14 (45.45%) Multiple Myeloma, 6 
(10.91%) Prostate Cancer, 8 (14.55%) had a diagnosis of Osteoporosis. And 7 (12.73%) 
presented other malignancies such as: Bone Cancer, Adenocarcinom, Bladder Cancer, 
Lung Cancer, No Hodgkin Lymphom and Polyarthritis. 
 
Figure 2: Differentiation of main diagnosis and reason for bisphosphonate therapy. 
 
VII.3 Bisphosphonate History 
 
The patients were mostly receiving their doses intravenously (49; 90.74 %) and only 5 
patients were taking oral bisphosphonates (9.26%). 
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 Of all patients, 36 (66.67%) received zolendronic acid 4mg intravenously every 3 to 4 
weeks, 6 (11.11%) received pamidronate disodium 90 mg intravenously at the same 
interval, 7 (12.96%) received both bisphosphonates, beginning with pamidronate and 
switching to zolendronic acid after a certain period. 
Of all patients, 5 (9.26%) were taking oral bisphosphonates, of these patients 3 (80%) 
were taking Fosamax 70mg once a week and only 1 (20%) was was taking Actonel 
30mg once a week. 
 
Bisphosphonats
66.67 11.11
12.96
9.26
Zometa
Aredia
Both
other
 
 
Figure 3: Differentiation of Bisphosphonate intake.  
 
 
 
The mean duration from the first use of the drug to the recognition by the patient or 
physician of sign or symptoms of ONJ was 39 months (range, 3 ± 168 months) 
The mean duration for each bisphosphonate are to be seen in the following table.  
 
Table 1: Months of Bisphonates intake 
 
 
 
 
  
 
 
Bisphosphonates intake 
 
Zometa Aredia Both Other 
Min 6 3 14 18 
Max 168 120 60 120 
Media 35 44.6 39.12 52.8 
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VII.4 Clinical Manifestations 
 
The location of the lesion was as follows: 11 (20.4%) patients presented a lesion in the 
maxilla (3 on the right side and 8 on the left side); 43 (79.6%) patients presented a 
lesion in the mandibular bone (17 on the right side, 23 on the left side and 3 on both 
sides).  
 
Table 2: Distribution of Clinical Manifestation 
Location 
Maxilla Mandible Right Left Both sides 
11 43 20 31 3 
20.4 79.6 37.0 57.4 5.6 
 
 
The first and most frequent first symptom was pain, being the reason for the patient to 
be evaluated. The patients presented the following first signs and symptoms: Pain on 26 
(48.15%), non-healing wounds on 12 (22.22%), swelling on 9 (16.67%), bone exposure 
on 4 (7.41%) but was seing in more patients in the next controls, and fistulae on 3 
(5.56%) 
 
Table 3: Distribution of First Symptomes 
1st  Symptome 
Non-healing Bone exposure Fistula Pain Swelling 
12 4 3 26 9 
22.22 7.41 5.56 48.15 16.67 
 
 
Most of the patients had more than one clinical manifestation of BRONJ. Detailed 
information was only available for 53 patients (96.36%). Of these patients, 6 (11.11%) 
presented halitosis, 9 (16.67%) hypesthesia, 25 (46.30%) pus exsudates and 26 (48.15) 
swelling. 39(72.22%) patients presented non-healing wounds after a procedure and 43 
(79.63%) showed exposed bone, which appeared spontaneously or after a procedure.  
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Table 4: Distribution of other Symptomes 
 
 
The size of the bone exposure was only available on 47 patients, which gave as a media 
size of 0.88cm 
 
VII.5 Triggering events 
 
Information on local events that triggered the BRONJ was available for 53 patients 
(96.36%). Before the occurrence of ONJ, 38 patients (71.70%) had a one or more tooth 
extracted, 1 (1.89%) received an implant and 3 (5.66%) received and implantat after a 
tooth extraction, 8 patients (15.09%) had other procedures including root canal or 
periodontal treatments. Lesions developed spontaneously in only 3 patients (5.66%) 
 
Table 5: Triggering procedures 
 
 
 
 
 
VII.6 Diagnostic tools 
 
Different diagnostic tools that were taking in consideration are the ones that were done 
at the first visit of the patient at the clinic of the university hospital. However, this 
information was not available for all patients or the procedures were made during the 
next visits. 
 
Other Symptomes 
hypaesth.  swelling pus halithosis  non healing 
exposed 
bone 
9 26 25 6 39 43 
16.67 48.15 46.30 11.11 72.22 79.63 
Ex Implant both others None Tx 
38 1 3 8 3 
         71.70             1.89             5.66           15.09             5.66  
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The level of leucocytes was only measured in 21 patients (38.4%). The media level was 
8.8 10E9/l (range; 2.91 ± 18.3 10E9/l). CRP was only measured in 19 patients (35.18%). 
The media level was 49.52  (range; 3 ± 180). 
 
Of the Patients with a CRP value, 7 (36.84%) had a Mama Ca., 4  (21.05%) had Multiple 
Myeloma and 3 (15.78%) had Protate Ca. And eventhogh they were all receiving IV 
Bisphosphonates, only 3 patients with Mama Ca and 2 patients with Prostate Ca. had a 
complete remission of the BONJ. 
Histopathology was available for 31 patients (57.4%). Of these patients 16 (51%) 
presented Actinomyces colonies, 19 (61.29%) presented bone necrosis, 1 (3%) 
presented partial necrosis and 7 (22.58%) presented osteomyelitis. Microbiology studies 
were only done in 9 patients (16.67%) and they did not succeed in culturing the 
Actinomyces or any other specific pathogen.   
 
Image diagnostic test included Orthopanthomgraphy, CT scans and MRIs.  It was found 
that these were done on the first visit on 27 (50%), 29 (53.70%) and 26 (48.15%) 
respectively.  The imaging was part of another study, so the imaging results were not 
followed in detail. 
 
VII.7 Treatment Protocols 
 
Treatment of the disease was done individually, depending on the severity, size 
dimension of the jaw necrosis and the underlying disease and general condition of the 
patient. Surgical treatments were done in 31 patients (57.47%) and no surgical 
treatments which involved only antibiotics were done in 23 patients (42.59%) 
 
Surgical procedures were considered from small wound curettage up tol an ostectomy of 
the necrotic bone or extensive resection.  Because in some cases more than one 
surgery was performed, in this thesis,  the first action of treatment that was performed is 
the only one being taken into consideration 
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In referral to the antibiotics intake, patients received either oral or intravenous amoxicillin 
(26 patients, 48.15%) depending on the severity of the cases. The patients with allergic 
reactions to penicillin, clindamicine (24 patients, 44.44%) was prescribed. These drugs 
were administered for a period of 1 to 16 weeks (media intake, 5.3 weeks) 
 
 
 
 
      Table 6: Antibiotics intake                               Table 7: Time period of Antibiotic intake 
 
VII.8 Follow ± up and treatment outcome 
 
Follow ± up information was available for 52 patients (96.30%) and ranged between 1 to 
208 weeks (4 years). Patient response was classified as follows: CR or complete 
remission when there was a complete resolution of the BRONJ, PR or partial remission, 
when there was a reduction of bone exposure, significant pain relief and cessation of 
pus exudaes and extraoral manifestations, and NR or no response when there was no 
sign of improvement.  
 
Of the patients, 21 (38.29%) had CR to therapy whereas 22 (40.74) had a PR and 10 
(18.52%) had NR. During the study 7 patients (12.96) died because of the main 
diagnosis not because of BRONJ.  
 
 
 
 
 
Figure 3 
Antibiotics 
Amoxiciline Clindamicine Others 
26 24 7 
48.15 44.44 12.96 
Antibiotics Duration in weeks 
Media 5.3 
Max 16 
Min 1 
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When evaluating which therapy had a better outcome, eventhough the final outcome 
varied in period of time and how many check ups were done to the patients, no 
significant difference was found between the CR group with 21 patients and PR group 
with 22 patients. Of the first group, 13 (61.90%) patients underwent surgery with either 
local or general anesthesics, and of the second group, 13 (59.09%) underwent therapy 
under the same conditions. And they also received antibiotics after surgery. 
 
In referal to the Antibiotics intake, only one patient who was receiving Amoxicilin with 
Clavulanic Acid for more than 12 weeks presented no improvement after this period of 
time.. Eventually she passed away during the study out of the bone cancer. 
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VIII. Discussion 
 
Every year, an estimated 30 million bisphosphonate prescriptions are written. It is 
estimated that pamidronate and zoledronate have been used in over 2.5 million patients 
worldwide33. 
 
The use of bisphosphonates in oncology has had a profound beneficial effect on the 
management of metastatic bone diseases and the prevention of treatment-induced bone 
loss until 2003, when a considerable side effect in the jaws was described.  
 
Our review shows that the patients presenting osteonecrosis after taking 
bisphosphonates were patients suffering from Osteoporosis, Breast and Prostate 
Cancer as well as Multiple Myeloma.  
 
The variable aspects of predisposing systemic and dental comorbidities, triggering 
events, duration of Bisphosphonate administration, treamtent protocols, and treatment 
outcomes have been discussed in the literature7,32,34,37.  
 
Our results are mainly compared with the one by Lazarovici37 et al in 2009. in which 105 
patients with BIONJ underwent follow-up, and data demogarphics, medical background, 
type and duration of BP use, possible triggering events, mode of therapy, and outcome 
were recorded. Information very similar to the one that it is being recollected in this 
paper. 
 
Of our patients, 78.18%  had undergone chemotherapy, compared with the 54% of the 
patients described by Lazarovici et al37. The difference is probably due to the fact that 
84.2 % of their patients had had Cancer where as 81.82% of our patients had 
Malignancies. 
 
An important issue discussed in the literature is the mean duration of bisphosphonates 
consumption before the development of BRONJ. The mean duration was 35 months for 
Zometa, 44.6 months for Aredia, and 52.8 months for other bisphosphonates (that 
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included Fosamax, Bonivia and Actomel) among our Patients. In the study of 
Lazarovici37, the mean duration was 27 months for Zometa, 48 months for Aredia and 67 
months for Fosamax. Marx et al32 study reported a mean duration of 9.4 month for 
Zometa, 14.1 months for Aredia and 36 months for Fosamax. 
 
There is a clear sign that Zometa has a greater pontency as the other bisphosphonates, 
which will produce an effect in a shorter period of time. Eventhough Fosamax results in 
our study were not taken separately; we can assume that its effect in time will be shown 
later, as reported by Lazarovici37 and Marx 7,19. 
 
Seven of our patients received 2 types of bisphosphonates. Most of them received 
Aredia unteil they were switched to Zometa. This 7(12.96%) of our patients received this 
combination for a mean of 39.12 months before any sign of osteonecrosis was shown.  
Lazarovici et al37 found a mean duration of 52 months before osteonecrosis of the jaw 
developed. This lenght of time was unexpectedly longer than the mean duration of 
Aredia and Zometa when administered alone. On the other hand, Marx et al30 reported a 
mean of only 12 months when a combined comsuption of both bisphosphonates was 
used. Our results show not such a big discrepancy between the intake of each 
bisphosphonate alone nor when taking together. 
 
Of our patients, 79.6% had the osteonecrosis developed in the mandible, 20.4% had 
lesions in the maxilla and no lesion was found in the palate. Lazarovici et al36 reported 
that 54% of their patients had lesions in the mandible, 34% of their patients had lesions 
in the maxilla, 11% in both jaws and 1% in the palate.  
In reference to the clinical manifestations, Lazarovici et al37 found that 55.4% of their 
patients initially presented with exposed bone, 67.32 with pus exudates and 73.26% with 
complaints of a painful sensation in the affected area, whereas 16.83 exhibited extraoral 
manifestations, such as swelling and fistulas, mostly in the submandibular area. When 
mesuring the first signs and symptoms, we found that 48.15% of the patients presented 
with pain, 22.22% of the patients with non-healing wounds, 16.67% of the patients with 
swelling, 7.41 % with bone exposure and 5.56% of the patients with fistulae. 
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Pain is clearly the most common symptom. However this information does not exclude 
the posibility that a patient could have had another manifestation at first and was not 
able to notice it. 
 
Information about other clinical manifestations was gathered through out the process, 
which was only available for 53 patients. From these, it was found that 79.63% of these 
patients showed exposed bone, which appeared spontaneously or after a procedure; 
46.30% had pus exudates, 48.15% had swelling, 11.11% presented halitosis, 16.67% 
hypesthesia, and 72.22% presented non-healing wounds after a procedure. 
 
Another important issue to discuss is the event that triggers the oral system to develop 
osteonecrosis. Eventhough there are many scientific studies proving the valuable use of 
bisphosphonates as a part of the oncology therapy, there is considerable evidence that 
long term bisphosphonate therapy can induce osteonecrosis, and that this necrotic 
processes are mostly initiated by local traumas or dental procedures38. 
 
Dentoalveolar surgery, such as tooth extraction or placement of a dental implant, has 
been sugested as a predisposing factor for the development of osteonecrosis of the 
jaws27,32. In our study, 50 patients (94.34%)  exhibited ONJ after a dentoalveolar surgical 
procedure, of these patients 71.70% had a tooth or more extracted as a triggering event. 
Lazarovici et al show that 47 patients (50%) had also undergone a dentoalveolar 
surgical procedure and that as well here the tooth extraction was the most prevalent 
event (37 patients). ONJ lesions emerged spontaneously in 3 (5.6%) of our patients, the 
figure was 40 (43%) in the study of Lazarovici37. 
 
When evaluating the patients we gathered information regarding their levels of 
leucocytes and CRP. Unfortunately, this information was not available in all patients and 
was not taken necesarely on the date of admission. In order to find a relevant 
information regarding this topic, further studies should be done. 
 
Actinomyces has been found to be detectable in a high percentage of patients suffering 
from infected osteonecrosis. Interestingly, Lugassy31 et al. described two patients with 
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severe osteomyelitis and presence of Actinomyces colonies after bisphosphonate 
therapy. Recently, Melo and Obeid35,38 reported on a similar case with Actinomyces 
osteomyelitis in a patient treated with zolendronate because of metastatic breast cancer. 
Lazarovici et al35 identified actinomyces in the histopahtologic examinations of 93% their 
cases. We found that out of the 31 patients, who had a histopathologic examination, 
51% contained actinomyces colonies. The actual role of this pathogen in the 
pathogenesis of osteonecrosis is still not clear. 
 
Because our study recollected data since 2003, when the first case of bisphosphonate 
induced osteonecrosis of the jaw was reported, there was not specific protocol of 
treatment. We found that during the first years, minivmal invasive surgery  with a 
conservative paleative use of antibiotics was the first option and within the time surgery 
has become the first choice.  
 
However, as mention before, it is only taken in consideration the first action of treatment 
that was performed, which resulted in 57.47% of our patients getting surgical treatments. 
No surgical treatments which involved only antibiotics were applied in 42.59% of the 
patients. Lazarovici et al36 developed a departmental treatment protocol, whose main 
goal was to provide a conservative paleative treatment. However surgery was performed 
on 24.75% of their patients.   
 
In Taiwan, Dr. Chiu39 and team studied 12 patients with diagnosed BRONJ. Modified 
therapeutic strategies for these patients were graded according to the severity of 
BRONJ. In the modified stage 2 patients (25%), antibiotic therapy of minor debridement 
surgery was useful for obtaining complete remission in all symptomatic patients. All 
modified stage 3 patients (75%) received antibiotic therapy, sequestrectomy, and 
debridement of necrotic bone.  
 
Antibiotics intake was administered to all of our patients, either with or without a previous 
surgery. Our patients received either oral or intravenous amoxicillin (48.15%) depending 
on the severity of the cases. Patients with allergic reactions to penicillin, recivied 
clindamicine (44.44%) instead.  Lazarovici et al37 administered oral amoxicillin to 50.49% 
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of their patients, IV penicillin to 8.91%, oral doxycycline to 27.725 of their patients, oral 
clindamycin to 9.9% of their patients and IV clindamycin to 1.98% of their patients. The 
antibiotics of choise remained the same in both studies. 
/D]DURYLFLHWDOµVFRQVHUYDWLYHSURWRFROWRJHWKHUZLWKDQHPSLULFDQWLELRWLc treatment led 
to the following results amor theri study patients: 16 (18%) had a CR, 45 (52%) had a 
PR, and only 26 (30%) had NR. These findings are similar to ours, which showed that 21 
(38.29%) had CR, 22 (40.74%) had a PR and 10 (18.52%) had NR.  
 
General data on treatment outcome of osteonecrosis of the jaw in the literature remains 
vague, and need to be evaluated. 
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IX. Conclusion 
 
Induced osteonecrosis of the jaws is one of the most studied pathology in these days. 
And eventhough there is considerable evidence that the use of bisphosphonates either 
orally or intravenously can induce jaw osteonecrosis, there is still a lot of information 
unknown. 
 
There is a broad agreement among reserarchers that the standard goal for controlling 
this type of osteonecrosis is to prevent it. However, in order to be able to prevent it, it is 
necessary to to know how it works since the very first start. 
  
After all these evidence, many believe that BRONJ is definitively caused by 
bisphosphonates. However, how sure we are about this. Are they really the cause? It is 
said that their point of action is to affect the bone turnover specially affecting the 
osteoclast function. But during the process of healing we can observe many different 
points that can be affected and that may lead us to think that bisphosphonate are acting 
in different levels.  
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